10.6084/m9.figshare.11594193.v1
Julia Paik
Julia
Paik
Sodium zirconium cyclosilicate: a profile of its use
Adis Journals
2020
Sodium zirconium cyclosilicate
hyperkalemia
hyperkalaemia
Adis Q&A
review
2020-02-14 03:06:10
Online resource
https://adisjournals.figshare.com/articles/online_resource/Sodium_zirconium_cyclosilicate_a_profile_of_its_use/11594193
<p>Compliance with ethical standards<b></b></p><p><b><br></b></p>
<p><i>Disclosure</i>: The preparation of this review was not
supported by any external funding.</p>
<p> </p>
<p><i>Conflicts of interest: </i>J. Paik is an
employee of Adis International Ltd./Springer
Nature, is responsible for the article content and declares no conflicts of
interest.</p><p><br></p><p>Additional information about this Adis Drug Review can be found <a href="http://www.springer.com/gp/adis/products-services/adis-journals-newsletters/adis-drug-reviews"><b>here</b></a></p><p><br></p><p>Abstract</p><p><br></p><p></p><p>Sodium zirconium cyclosilicate (SZC) [Lokelma<sup>™</sup>] is a useful,
orally-administered option for the treatment of hyperkalaemia in adults. As a
non-absorbed, non-polymer compound, SZC lowers serum potassium levels by
binding potassium in the gastrointestinal (GI) tract and promoting faecal
potassium excretion. SZC is effective in restoring and maintaining
normokalaemia and is generally well tolerated; most adverse events (AEs)
reported in phase 3 clinical trials were manageable without treatment
interruption. SZC
appears to be effective and generally well tolerated regardless of common
factors associated with hyperkalaemia, including concomitant renin-angiotensin-aldosterone
system inhibitor (RAASi) therapy, chronic kidney disease, diabetes and heart
failure. Recent data suggest that SZC is also effective and similarly well
tolerated in patients with end-stage kidney disease (ESKD) receiving
haemodialysis, who typically have persistent predialysis hyperkalaemia. Real-world
data and additional long-term data will be valuable in more definitively
establishing the position of SZC in the treatment of hyperkalaemia.</p><br><p></p><p></p><p><b>©</b> Springer
Nature Switzerland AG 2020</p><p></p>